714 results about "Dementia" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention relates to the technical field of health information, in particular to a dementia risk prediction system based on an associated information processing model, and the system firstly extracts multi-modal hidden variable features through a data processing module, and generates an individualized risk feature matrix through causal reasoning and association rule optimization. And then, the system dynamically generates a personalized intervention path by adopting a reinforcement learning optimization algorithm, and realizes long-term risk prediction through a recurrent neural network. The system outputs personalized prediction reports including dementia risk assessment, trend analysis and intervention suggestions. Experiments show that the accuracy of dementia risk prediction, the dynamic adaptability of an intervention strategy and the efficiency of health management can be remarkably improved.

The subject invention pertains to an artificial intelligence-aided classification system for Alzheimer's disease (AD) screening from retinal photographs, which includes a three-in-one deep learning (DL)-based pre-diagnosis module for image assessment and a DL-based AD classification module with additional heatmaps for visualization. For the AD classification module, three kinds of DL models predict the AD-dementia / non-demented probabilities from three directions with both eyes' four images (Direction-1), both eyes' four images combing demographical information (Direction-2), and a single eye's two images (Direction-3), respectively. For the pre-diagnosis image assessment, embodiments provide one pre-processing model, with three additional models for each of the three classification tasks, including image-quality (e.g., gradable or ungradable), field-of-view (e.g., macula-centered or optic nerve head-centered), and laterality-of-the-eye (e.g., right or left eye). Also included is a cloud-based web application that can output the pre-diagnosis image assessment and a simple binary AD-dementia / non-demented classification based on retinal photographs.

The embodiment of the invention relates to a processing method and device of an Alzheimer disease risk prediction model. The method comprises the steps that DT I-ALPS feature information of dementia crowds and healthy crowds of a specified age group is obtained in a big data collection and volunteer recruitment mode, and a corresponding model data set is constructed and recorded as a first data set; constructing a three-classification prediction model for predicting the risk of the Alzheimer's disease as an Alzheimer's disease risk prediction model corresponding to a specified age group; training an Alzheimer disease risk prediction model based on the first data set; after model training is finished, DT I-ALPS feature information, input by the user, of any tested person of the specified age group is input into the Alzheimer disease risk prediction model for prediction, and a corresponding classification probability vector is obtained and fed back to the current user. According to the invention, prediction accuracy and prediction stability can be improved.

Systems and methods are provided for assisting individuals with physical and / or cognitive ailments, such as dementia, Alzheimer's disease, and / or visual impairment. The quality of life, safety, and / or autonomy of such individuals can be enhanced by utilizing a combination of sensors, actuators, augmented reality (AR) technology, and machine learning (ML) algorithms. The sensors and actuators can include (but are not limited to) cameras, global positioning system (GPS) sensors, accelerometers, motion sensors, AR visual systems, headphones, microphones, haptic feedback systems, and / or connectivity capabilities (wired and / or wireless) to provide information about the surrounding environment and events. By leveraging advanced sensor technology, AR, and real-time data processing, a comprehensive support system can be provided that addresses the unique challenges faced by these individuals on a daily basis.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention provides an Alzheimer disease auxiliary accurate identification method and system based on a multi-omics marker network and an adaptive support vector machine. Accurate identification of Alzheimer's disease and other types of dementia is realized through a marker network based on five modal data and an adaptive support vector machine model. According to the method, multi-source heterogeneous data such as blood, urine, neuroimaging, electrophysiology and clinical evaluation are fused, specific markers are analyzed and screened by adopting a weighted gene co-expression network, and cross-modal feature interactive learning is realized through a self-attention mechanism. An online learning mechanism is introduced to enable the model to adapt to new data distribution, and the contribution degree of each marker to diagnosis is output in combination with an interpretability module. Finally, multi-center data synchronization and model optimization are realized by means of a cloud platform, the accuracy, specificity and early diagnosis capability of AD diagnosis and identification and the adaptability of the model are remarkably improved, the limitation of the prior art is overcome, and doctors are assisted to diagnose and treat the Alzheimer's disease.

The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and / or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.

To provide a dementia risk presentation system of presenting a user's risk of the dementia.SOLUTION: A presentation system 10 includes: a first database 17 in which sample brain health data 17a is associated with individual characteristics 17b, where the sample brain health data include at least any of sample brain state data 17d, the data relating to a state of the brain of a sample object person, and sample cognitive ability data 17e, the data relating to cognitive ability that is a function of the brain, and where the individual characteristics include at least one of an age, a gender, and physical information of the sample object person; a first recognition section 11 for recognizing user brain health data 18a including at least any of user brain state data 41 and user cognition ability data 61; a second recognition section 12 for recognizing user individual characteristics 43; and a risk presenting section 30 for presenting a chronological transition line 52 representing transition in the user brain health data from the past to the present of the user, and a risk line 54 relating to the dementia.SELECTED DRAWING: Figure 1

The invention discloses an intelligent cognitive assessment method and system based on a virtual reality environment. According to the method, through accurate eye movement calibration and electroencephalogram calibration, resting-state electroencephalogram information, digital cognitive evaluation task parameters and eyeball movement track parameters of a subject in a virtual reality environment are collected, and through professional preprocessing and feature extraction, deep analysis and fusion are conducted on data through a common-attention multi-mode feature noise reduction fusion model. Through training and prediction of the neural network model, the cognitive function state of the subject can be effectively evaluated, the accuracy and efficiency of cognitive evaluation are improved, and meanwhile, the user experience is optimized. By utilizing the method, early recognition of cognitive impairment is facilitated, a scientific basis is provided for clinical diagnosis and intervention, and the method is of great significance in preventing and delaying dementia of old people.

The present application provides a light treatment device for suppressing or preventing Alzheimer's disease. A light treatment device includes a carrier structure and an array of near-infrared irradiation units. The bearing mechanism forms an accommodating space for the head of the object and bears the array of the near-infrared irradiation units. The array of near-infrared irradiation units is configured such that near-infrared light is emitted into the accommodation space, when the head of the subject is in place, an irradiation space range covering at least the anterior upper cranial portion, the top cranial portion, the left cranial portion and the right cranial portion is formed, and the time-average total irradiation power of the head cover portion acting on the head of the subject is 27.5 W or more, 31 W or more, 40 W or more, or 60 W or more, and the irradiation power of the head cover portion acting on the head of the subject is 27.5 W or more, 31 W or more, 40 W or more, or 60 W or more. Or more than 70W, and the space-time average optical power density irradiated to each part does not exceed 230mW / cm < 2 >. The light treatment device does not depend on nasal and ocular irradiation, achieves an optimized treatment effect on AD patients from MCI to dementia during the course of treatment, and not only effectively maintains the treatment effect but also continuously increases the treatment effect when the light treatment is interrupted.

An apparatus and method for aiding in the detection of dementia, concussion, other neurologic conditions, retinal, and optic nerve conditions. The apparatus enables the diffusion coefficient of the tissue to be ascertained and studied by directing the light from a laser or other coherent light source at the patient's retina, optic nerve or choroid and measuring the fluctuations in the intensity of the back-scattered light caused by the movement of light scatterers in the tissue. By comparing the measurements to a normal database, or to the subject's previous measurement, in combination with an eye examination and OCT image / measurement the changes caused by the disease and the effectiveness of therapy can be ascertained. The disclosed apparatus allows the incident and detection optics to be attached to ophthalmic devices typically used in ophthalmologic care. Also, where both the incident laser fiber optic and the detection fiber optic are directly connected to goggles, one or more or all of the above-described mirrors may not be necessary, as both fiber optics are preferably directly directed into the eye.

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses a dementia identification method based on brain computer network space cross attention fusion. The dementia identification method comprises the steps that resting-state electroencephalogram signals are acquired, preprocessing and brain network construction are carried out, the frequency band power ratio is calculated, and a training set and a test set are divided; the brain network fuses the spatial information, and spatial features are obtained through an isotropic graph neural network and a local feature enhancement module; the frequency band power ratio is coded by a multi-layer perceptron to obtain frequency spectrum statistical characteristics; a bidirectional cross attention module is input, and complementary fusion features are extracted; and performing mixed pooling and splicing on the complementary fusion features, then sending the fused features to a Chebyshev Kolmogorov-Arnold network classifier, and outputting an Alzheimer's disease / frontotemporal dementia / health control (AD / FTD / HC) classification result and a cognitive scale evaluation score (MMSE). According to the method, the multi-feature complementary information is effectively integrated through joint modeling of the spatial diagram features and the global spectrum features, and the accuracy, stability and generalization ability of AD and FTD classification in a complex brain network are improved.

A method is provided that includes non-invasively applying a first non-invasive sphenopalatine ganglion (SPG)-stimulation electrode to a first SPG-stimulation site of a subject on an external surface of skin between a mandibular notch and a zygomatic process of a temporal bone, the subject identified as at risk of or suffering from dementia. A second SPG-stimulation electrode is applied to a second SPG-stimulation site of the subject. Cerebral blood flow (CBF) of the subject is increased by activating circuitry to drive, between the first non-invasive SPG-stimulation electrode and the second SPG-stimulation electrode, alternating current configured to stimulate an SPG of the subject. Other embodiments are also described.

The invention relates to an intelligent defecation system and a using method thereof, and the intelligent defecation system comprises an implantable anus valve which is used for controlling defecation; the pressure sensor is used for monitoring the pressure generated in the anus area during defecation or fart in real time; the implantable power supply is used for supplying power to the implantable anus valve and the pressure sensor; the wireless charging inner module is used for charging the implantable power supply; the control chip is used for receiving the pressure data of the pressure sensor and the electric quantity data of the implantable power supply and controlling the opening and closing of the implantable anus valve by controlling the on-off of the implantable power supply; and the control system is used for receiving the signal from the control chip and sending an instruction to the control chip. According to the intelligent defecation system and the using method thereof, intelligent defecation control is achieved, operation is easy, defecation of disabled old people defecating anywhere due to dementia and patients with anal sphincter dysfunction or anus resection caused by specific diseases are controlled, fecal incontinence is avoided, and life quality is improved.

In certain embodiments a light therapy system (e.g., phototherapy device), such as for treatment of Alzheimer's disease, depression, dementia, short-term memory, or for improved learning, improved athletic performance or improved cognitive performance, is provided where the light system comprises a blue light source that operates at a frequency in the range from 20 to 50 Hz (preferably around 40 Hz), whereby the system enables retinal ganglion cells of a human to be exposed in order to stimulate brain waves (gamma oscillations in the human's brain).

To cause the elderly living far away to delay dementia through conversations with a family.SOLUTION: A system according to an embodiment comprises: an acquisition unit; a generation unit; and a dialogue unit. The acquisition unit is configured to acquire voice data on a family of an elderly. The generation unit is configured to, on the basis of the voice data acquired by the acquisition unit, generate a model of a voice of the family, using a model generated by the generation unit. The dialogue unit is configured to perform a dialogue with the elderly using the model generated by the generation unit.SELECTED DRAWING: Figure 1

The invention discloses a dementia intervention scheme recommendation method and system based on a knowledge graph, and relates to the technical field of intelligent medical treatment and artificial intelligence. And constructing a dementia intervention knowledge graph containing patients, symptoms, intervention measures and environmental elements. And performing intelligent semantic reasoning on the short-term state, the long-term behavior mode and the nursing environment of the patient by fusing multi-level reasoning and situational reasoning, generating a candidate intervention scheme matched with the current state of the patient, and outputting a personalized recommendation result. In the intervention implementation process, the knowledge graph association relation is dynamically updated based on patient behavior feedback and symptom changes, and continuous optimization and self-adaptive adjustment of an intervention scheme are achieved. According to the method, the individuation level, long-term adaptability and safety of dementia intervention recommendation are improved, and the method is suitable for clinical and long-term nursing scenes.

Provided is a data processing system capable of detecting that a user may have initial symptoms of dementia.　The data processing system comprises: a necklace-type terminal including a microphone that collects a user utterance of a wearer, a collection unit that collects an output of the microphone, and a communication unit that transmits the output of the microphone collected by the collection unit to an external device; and a data processing device. The data processing device includes: an input unit that receives the user utterance collected by the microphone; and a processing unit that, when a remark indicating a sign of dementia is included in the user utterance, notifies a preset notification destination that the wearer may have dementia.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a microtubule associated protein tau (MAPT) gene. The MAPT RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a MAPT gene. The MAPT RNAi agents are conjugated to an antigen binding protein that may enable subcutaneous delivery of the RNAi agents by facilitating crossing of the blood brain barrier (BBB). Pharmaceutical compositions that include one or more MAPT RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described MAPT RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of MAPT gene expression and a reduction in MAPT activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including Alzheimer's disease, Frontotemporal lobar degeneration dementia (FTLD), Progressive supranuclear palsy, and other tauopathies.

In an embodiment, a system for digital engagement is disclosed that is configured to operate an application for a patient with dementia. The application includes at least one applied virtual environment. The system is further configured to evaluate input of the patient based on a mixed model for observing digital engagement, and to engage the patient with the application using dialogue delivered by at least one virtual avatar, the virtual avatar being supported by artificial intelligence and the dialogue being determined based on the evaluated input. The system is further configured to log and evaluate progress data of the patient and to provide feedback and support based on the evaluated progress data.

To provide a system capable of achieving support for elderly people living alone and early detection of dementia.SOLUTION: Provided is a system with an AI partner that can be customized according to a user's preferences and interests, the system comprising: means for estimating an emotional state judging from the user's tone of voice, manner of speaking, used words, etc. with help of an emotion engine; means for generating prompt sentences to instruct generation of appropriate contents of conversation according to a current emotional state of the user on the basis of the estimated emotional state of the user; means for generating contents of conversation with the user using the generated prompt sentences and the AI partner; means for replying the generated contents of conversation to the user with voice or text; means for finding out an early symptom of dementia through conversation with the user by analyzing changes, etc. in conversation patterns and memory in a short period of time; and means for transmitting an alert to his / her family or a medical institution if the user shows a symptom that may be dementia.SELECTED DRAWING: Figure 1

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PRNP RNA in a cell or animal, and in certain instances reducing the amount of PrP protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks spongiform changes in the brain, development of abnormal protein aggregates, neuronal loss, markers of neuronal loss, rapidly progressing dementia, and death. Such neurodegenerative diseases include prion diseases, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), familial Creutzfeldt-Jakob Disease (fCJD), Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, kuru, Alzheimer's disease, or Parkinson's disease.